Meta-analysis: Omadacycline therapy for complicated skin and soft tissue infections

Summaries 2 min 635

Font Size

Created On: 20/06/2024

Meta-analysis aimed to compare the clinical efficacy and safety of the FDA-approved broad-spectrum antibiotic- Omadacycline with other treatments for complicated skin and soft tissue infections (complicated SSTIs) in adults.

See All

Key take away

Omadacycline antibiotic therapy shows comparable efficacy and safety to Linezolid for treating complicated skin and soft tissue infections in adults.

Background

Method

A search of randomized controlled trials (RCTs) investigating the use of Omadacycline for complicated SSTIs across multiple databases including PubMed, Embase, Cochrane, Web of Science, and Clinical Trial was conducted. The main focus was on evaluating clinical efficacy and microbiological response as primary outcomes, with safety as a secondary outcome.

Result

Four RCTs involving 1,757 patients, with linezolid as the comparator drug were evaluated. In terms of clinical efficacy, Omadacycline demonstrated non-inferiority to linezolid in both the modified intent-to-treat population (OR: 1.24, 95% CI: [0.93, 1.66], P = 0.15) and the clinically evaluable population (OR: 1.92, 95% CI: [0.94, 3.92], P = 0.07).

Regarding microbiological response, Omadacycline showed slightly higher rates compared to linezolid in both the microbiologically evaluable population (OR: 1.74, 95% CI: [0.81, 3.74], P = 0.16) and the microbiological modified intent-to-treat population (OR: 1.27, 95% CI: [0.92, 1.76], P = 0.14).

There were no substantial differences observed in subgroups with monomicrobial or polymicrobial mixed infections. Similar rates of mortality and adverse event rates were observed between Omadacycline and the comparator drug.

Conclusion

Omadacycline demonstrated comparable clinical efficacy and microbiological response to linezolid, with similar safety profiles in complicated SSTIs treatment, suggesting Omadacycline to be beneficial for adults with complicated SSTIs.